Patient demographics
| Age, years, mean (SD) | 65.2 (14.6) |
| Men, n (%) | 9 (32.0) |
| Women, n (%) | 16 (68.0) |
| T1D, n (%) | 13 (52.0) |
| T2D, n (%) | 12 (48.0) |
| Duration of DM, years, mean (SD) | 19.4 (11.7) |
| DM medications, n (%): | |
| Metformin | 11 (44.0) |
| Sulphonylurea | 3 (12.0) |
| DPP-IV inhibitor | 3 (12.0) |
| SGLT-2 inhibitor | 4 (16.0) |
| Pioglitazone | 0 (0) |
| GLP-1RA | 2 (8.0) |
| Insulin: | 17 (68.0) |
| basal | 1 (4.0) |
| basal bolus | 13 (52.0) |
| premixed | 1 (4.0) |
| pump | 2 (8.0) |
| HbA1c, mmol/mol, mean (SD) | 84.7 (29.8) |
| Creatinine, μmol/L, mean (SD) | 92.5 (70.3) |
| eGFR, mL/min/1.73m2, mean (SD) | 65.2 (24.5) |
| Comorbidities, n (%): | |
| Cerebrovascular disease | 3 (12.0) |
| Chronic kidney disease | 4 (16.0) |
| Coronary artery disease | 7 (28.0) |
| Lung disease | 4 (16.0) |
| Malignancy | 4 (16.0) |
| Peripheral vascular disease | 9 (36.0) |
DM = diabetes mellitus; DPP-IV = dipeptidyl-peptidase-4; eGFR = estimated glomerular filtration rate; GLP-1RA = glucagon-like peptide-1 receptor analogue; HbA1c = glycated haemoglobin; SGLT-2 = sodium-glucose co-transporter-2; T1D = type 1 diabetes; T2D = type 2 diabetes.